Patents by Inventor Jameel Shah

Jameel Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8624027
    Abstract: The present disclosure relates to a combination of therapeutic agents for use in treating a patient a subject suffering from cancer. In addition, the present disclosure also relates to diagnostic assays useful in classification of patients for treatment with one or more therapeutic agents.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: January 7, 2014
    Assignee: AbbVie Inc.
    Inventors: Omar Jameel Shah, Yu Shen, Xiaoyu Lin, Mark Anderson, Xiaoli Huang, Junling Li, Leiming Li
  • Publication number: 20100227838
    Abstract: The present disclosure relates to a combination of therapeutic agents for use in treating a patient a subject suffering from cancer. In addition, the present disclosure also relates to diagnostic assays useful in classification of patients for treatment with one or more therapeutic agents.
    Type: Application
    Filed: December 4, 2009
    Publication date: September 9, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Omar Jameel Shah, Yu Shen, Xiaoyu Lin, Mark Anderson, Xiaoli Huang, Junling Li, Leiming Li
  • Publication number: 20100196907
    Abstract: The present invention relates to identifying the presence or absence of one or more copy number gains in the ABCB1 gene, the ABCB4 gene or combinations thereof, identifying patients eligible to receive Aurora kinase inhibitor therapy, either as monotherapy or as part of combination therapy, and monitoring patients' response to such therapy.
    Type: Application
    Filed: January 29, 2010
    Publication date: August 5, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Dimitri Semizarov, Jameel Shah, Jun Guo, Mark G. Anderson
  • Publication number: 20090203671
    Abstract: Methods of treating cancer in patients comprising administering thereto aurora kinase inhibitors and TRAIL (tumor necrosis factor (TNF)-related apoptosis inducing ligand) inhibitors is disclosed.
    Type: Application
    Filed: November 25, 2008
    Publication date: August 13, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Keith B. Glaser, Omar Jameel Shah